Biological Evaluation of Isoniazid Derivatives as an Anticancer Class
AbstractA series of thirty-two isoniazid derivatives have been evaluated for their activity against four human cancer cell lines with potent cytotoxicity (IC50 ranging from 0.61 to 3.36 μg/mL). The structure-activity relationship (SAR) analysis indicated the number, the positions, and the types of substituents attached to the aromatic ring as being critical factors for the biological activity. Briefly, we observed that the presence of a hydroxyl group on the benzene ring plays an important role in the anticancer activity of this series, especially when it is located in ortho-position. Among the thirty-two compounds, three displayed good cytotoxic activity when compared to the reference drug doxorubicin and are thus being considered leading compounds of this new class.
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
RODRIGUES, F.A.R.; OLIVEIRA, A.C.A.; CAVALCANTI, B.C.; PESSOA, C.; PINHEIRO, A.C.; DE SOUZA, M.V.N. Biological Evaluation of Isoniazid Derivatives as an Anticancer Class. Sci. Pharm. 2014, 82, 21-28.
RODRIGUES FAR, OLIVEIRA ACA, CAVALCANTI BC, PESSOA C, PINHEIRO AC, DE SOUZA MVN. Biological Evaluation of Isoniazid Derivatives as an Anticancer Class. Scientia Pharmaceutica. 2014; 82(1):21-28.Chicago/Turabian Style
RODRIGUES, Felipe A.R.; OLIVEIRA, Augusto C.A.; CAVALCANTI, Bruno C.; PESSOA, Claudia; PINHEIRO, Alessandra C.; DE SOUZA, Marcus V.N. 2014. "Biological Evaluation of Isoniazid Derivatives as an Anticancer Class." Sci. Pharm. 82, no. 1: 21-28.